Verition Fund Management
ABOS icon

Verition Fund Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Verition Fund Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,445
Closed -$33.4K – 3287
2024
Q4 		$33.4K Buy
+19,445
New +$46.8K ﹤0.01% 3147
2023
Q4 		– Sell
-23,500
Closed -$97.5K – 2290
2023
Q3 		$97.5K Buy
+23,500
New +$145K ﹤0.01% 2124

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Verition Fund Management's ABOS Position: Q1 2025 in Review

Verition Fund Management sold out of Acumen Pharmaceuticals (ABOS) in Q1 2025, closing a stake of 19,445 shares — an estimated $33.4K sold.

Verition Fund Management first reported a position in ABOS in Q3 2023 and held it in 2 quarters. The position peaked at $97.5K in Q3 2023. 81 funds tracked by Wall St. Rank hold ABOS as of Q1 2025.

  • Verition Fund Management reported no remaining Acumen Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 19,445 Acumen Pharmaceuticals shares in Q1 2025, an estimated $33.4K.
  • Verition Fund Management first reported a position in Acumen Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Verition Fund Management's Acumen Pharmaceuticals position peaked at $97.5K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.